BMS453 manufacturers
- BMS453
-
- $58.00 / 5mg
-
2025-11-10
- CAS:166977-43-1
- Min. Order:
- Purity: 99.93%
- Supply Ability: 10g
|
| Product Name: | BMS453 | | Synonyms: | BMS453;4-[(1E)-2-(5,6-Dihydro-5,5-dimethyl-8-phenyl-2-naphthalenyl)ethenyl]-benzoicacid;(E)-4-[2-(5,6-Dihydro-5,5-dimethyl-8-phenyl-2-naphthalenyl)ethenyl]-benzoic acid;Benzoic acid, 4-[(1E)-2-(5,6-dihydro-5,5-dimethyl-8-phenyl-2-naphthalenyl)ethenyl]-;(E)-4-[2-(5,5-Dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl)vinyl]benzoic acid;BMS-189453
(BMS189453;Inhibitor,BMS453,retinoid,RAR/RXR,inhibit,BMS-453,BMS 189453,TGFβ,breast,RARβ,RARγ,Retinoid X receptors,BMS189453,arrest,cell,RARα,Retinoic acid receptors;BMS453, 10 mM in DMSO | | CAS: | 166977-43-1 | | MF: | C27H24O2 | | MW: | 380.48 | | EINECS: | | | Product Categories: | | | Mol File: | 166977-43-1.mol |  |
| | BMS453 Chemical Properties |
| Boiling point | 560.9±50.0 °C(Predicted) | | density | 1.167±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble10mg/mL, clear | | form | powder | | pka | 4.27±0.10(Predicted) | | color | white to beige |
| | BMS453 Usage And Synthesis |
| Uses | BMS 453 is a synthetic retinoid and RARβ antagonist which also displays antagonist acitivity in RARα. | | Definition | ChEBI: BMS-453 is a member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer). It is a potent retinoic acid receptor gamma (RARbeta) agonist that acts as an antagonist against RARalpha and RARgamma. It has a role as a retinoic acid receptor beta agonist, a retinoic acid receptor gamma antagonist, a retinoic acid receptor alpha antagonist and a teratogenic agent. It is a member of dihydronaphthalenes, a member of benzoic acids and a stilbenoid. | | Biological Activity | BMS-189453 is a potent RARβ agonist th at acts as an antagonist against RARα and RARγ. BMS-189453 induces RARβ reporter gene expression at sub nanomolar levels, and is 30 fold more potent than all-trans retinoic acid for inducing TGFβ activity in normal breast cells. The compound BMS-189453 does not transactivate RARα or γ transcriptional activity, but binding to those family members induces a strong transrepression of phorbol ester-induced AP-1 activity (IC50 = 0.1 nM in HeLa and MCSF-7). BMS-189453 significantly increases the efficiency of cardiac differentiation of hESCs.', 'BMS-189453 specifically has sufficient bioavailability in rats and monkeys. BMS-189453 only binds to α, β, and γ retinoid receptors but its activation is unknown. BMS-189453 is found to inhibit the action of collagenase-3 (MMP-13) which catalyses cartilage matrix degradation. Thus, it serves to tre at rheumatoid arthritis. |
| | BMS453 Preparation Products And Raw materials |
|